D. Gibson

发表

Subclassification of small bowel Crohn's disease using magnetic resonance enterography: a review using evidence-based medicine methodology.

D. Murphy, D. Malone, D. Murphy, 2015, Clinical radiology.

CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis

H. Mulcahy, G. Horgan, D. Keegan, 2017, Journal of clinical gastroenterology.

Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease

S. Robson, A. Cheifetz, T. Rispens, 2015, Inflammatory bowel diseases.

A prospective study of faecal immunochemical testing following polypectomy in a colorectal cancer screening population

K. Sheahan, H. Mulcahy, G. Horgan, 2017, Frontline Gastroenterology.

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

P. Gibson, K. Taylor, M. Sparrow, 2020, Alimentary pharmacology & therapeutics.

An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.

C. Redmond, H. Mulcahy, D. Keegan, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Infliximab is safe and induces sustained remission with complete mucosal healing in Crohn's disease in a patient with pan resistant pseudomonas cystic fibrosis: a case report.

C. Gallagher, G. Doherty, D. Gibson, 2014, Journal of Crohn's & colitis.

DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.

J. Mill, R. Harris, Eimear Crowe, 2016, Journal of Crohn's & colitis.

Early Assessment With Gastrointestinal Ultrasound in Patients Hospitalised for a Flare of Ulcerative Colitis and Predicting the Need for Salvage Therapy: A Pilot Study.

P. Gibson, K. Taylor, A. Friedman, 2021, Ultrasound in medicine & biology.

Fast and Curious: An Algorithmic Approach to Infliximab Dosing in Acute Severe Ulcerative Colitis

G. Doherty, D. Gibson, 2020, Digestive Diseases and Sciences.

Keeping the Bowel Regular: The Emerging Role of Treg as a Therapeutic Target in Inflammatory Bowel Disease

G. Doherty, E. Ryan, D. Gibson, 2013, Inflammatory bowel diseases.

Magnetic resonance enterography findings as predictors of clinical outcome following antitumor necrosis factor treatment in small bowel Crohn’s disease

H. Mulcahy, D. Keegan, D. Malone, 2015, European journal of gastroenterology & hepatology.

Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction

Á. Keogh, H. Mulcahy, D. Keegan, 2019, Frontline Gastroenterology.

Fecal Infliximab Loss.

G. Doherty, D. Gibson, 2015, Gastroenterology.

Editorial: infliximab de‐escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy—early promise but more data needed

M. Ward, D. Gibson, 2019, Alimentary pharmacology & therapeutics.

Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.

H. Mulcahy, D. O'Donoghue, T. Mooney, 2019, Gastrointestinal endoscopy.

Keeping the Bowel Regular: The Emerging Role of Treg as a Therapeutic Target in Inflammatory Bowel Disease

G. Doherty, E. Ryan, D. Gibson, 2013, Inflammatory bowel diseases.

DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.

J. Mill, Eimear Crowe, K. Malone, 2016, Journal of Crohn's & colitis.